Traduction de «will be included » (Néerlandais → Français) :

TERMINOLOGIE

Omschrijving: Het dragen van kleding van de andere sekse hoofdzakelijk om wille van de seksuele opwinding en om het beeld van iemand van de andere sekse op te roepen. Fetisjistisch transvestitisme wordt onderscheiden van transseksueel transvestitisme op grond van het duidelijk samengaan ervan met seksuele prikkeling en het sterke verlangen de kleding uit te trekken nadat het orgasme is opgetreden en de seksuele opwinding afneemt. Het kan voorkomen als een vroege fase in de ontwikkeling van transseksualiteit. | Neventerm: | transvestitistisch fetisjisme
Définition: Port de vêtements du sexe opposé, principalement dans le but d'obtenir une excitation sexuelle et de créer l'apparence d'une personne du sexe opposé. Le travestisme fétichiste se distingue du travestisme transsexuel par sa nette association avec une excitation sexuelle et par le besoin de se débarrasser des vêtements une fois l'orgasme atteint et l'excitation sexuelle retombée. Il peut survenir en tant que phase précoce du développement d'un transsexualisme. | Fétichisme avec travestisme

TRADUCTIONS EN CONTEXTE

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

The agenda items for the first meeting will include the appointment of the president and vice-president, the drafting and approval of the commission’s rules and regulations and determining the dates of meetings.
The agenda items for the first meeting will include the appointment of the president and vice-president, the drafting and approval of the commission’s rules and regulations and determining the dates of meetings.

Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.
This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.

Proactive contacts with the general and specialised press, various publications and information campaigns will be included together with future internal communication actions in a proper communication plan so as to implement a strategic communication policy as quickly as possible.
Proactive contacts with the general and specialised press, various publications and information campaigns will be included together with future internal communication actions in a proper communication plan so as to implement a strategic communication policy as quickly as possible.

Results of operations from this acquisition will be included retroactive to the acquisition date in the Group’s results for the fourth quarter of 2009.
Les résultats des opérations découlant de cette acquisition seront inclus rétroactivement à la date d’acquisition dans les résultats du Groupe au quatrième trimestre 2009.

In addition, a fourth business for primary care medicines, including the cardiovascular portfolio, will be consolidated into four regional units (reduction from the current five units).
En outre, un quatrième secteur d’activité pour les médicaments destinés aux soins de santé primaires, comprenant le portefeuille cardiovasculaire, sera consolidé en quatre (cinq actuellement) unités régionales.

Exceptional items: Other expense includes initial charges for an IT restructuring project which over time will exceed the USD 25 million threshold.
Eléments exceptionnels: Autres charges comprend les premières charges d’un projet de restructuration de l’informatique qui au final excédera le seuil d’USD 25 millions.

The fourth quarter of 2009 includes A(H1N1) pandemic flu vaccine sales totaling USD 1.0 billion, which will not recur in 2010.
Le quatrième trimestre 2009 comprenait un chiffre d’affaires d’USD 1,0 milliard pour les vaccins contre la pandémie de grippe A(H1N1) qui ne sera pas réitéré en 2010.

2010 outlook (Barring unforeseen events) At the half-year stage we raised our sales guidance to mid- to high-single-digit in constant currency, excluding Alcon. For the full year, Group sales will include four months of Alcon and this is expected to take constant currency sales growth into the low- to mid-teens.
Perspectives 2010 (sauf événements imprévus) En milieu d’année, nous avons relevé nos objectifs de chiffre d’affaires à un taux à un chiffre dans la partie moyenne à haute de la fourchette à taux de change constants, hors Alcon Pour l’exercice complet, le chiffre d’affaires du Groupe inclura quatre mois d’Alcon ce qui devrait hisser la croissance à taux de change constants à un taux à deux chiffres dans la partie basse à moyenne de la fourchette.